Q2 2023 13F Holders as of 30 Jun 2023
-
Type / Class
-
Equity / Common Stock, par value $0.001 per share
-
Shares outstanding
-
53,136,600
-
Number of holders
-
74
-
Total 13F shares, excl. options
-
34,283,564
-
Shares change
-
-1,402,460
-
Total reported value, excl. options
-
$257,463,245
-
Value change
-
-$6,376,896
-
Put/Call ratio
-
12.58%
-
Number of buys
-
37
-
Number of sells
-
-40
-
Price
-
$7.51
Significant Holders of ALX ONCOLOGY HOLDINGS INC - Common Stock, par value $0.001 per share (ALXO) as of Q2 2023
101 filings reported holding ALXO - ALX ONCOLOGY HOLDINGS INC - Common Stock, par value $0.001 per share as of Q2 2023.
ALX ONCOLOGY HOLDINGS INC - Common Stock, par value $0.001 per share (ALXO) has 74 institutional shareholders that have filed 13F forms with the Securities Exchange Commission (SEC).
These institutions hold a total of 34,283,564 shares
of 53,136,600 outstanding shares and own 64.52% of the company stock.
Largest 10 shareholders include venBio Partners LLC (9,699,925 shares), FMR LLC (6,130,539 shares), Vivo Capital, LLC (4,220,048 shares), ORBIMED ADVISORS LLC (2,871,000 shares), BlackRock Inc. (1,788,760 shares), Redmile Group, LLC (1,283,289 shares), BRAIDWELL LP (1,249,900 shares), VANGUARD GROUP INC (1,006,588 shares), Logos Global Management LP (1,000,000 shares), and Cormorant Asset Management, LP (612,079 shares).
This table shows the top 74 institutional shareholders of the company equity. This data is sourced directly from the SEC via 13F filings.
| Investor |
Option |
Weight % |
Change % |
Value $ |
* Price $ |
Shares |
Share Change |
Activity |
Report Period |
* Reported Price is the price of the security as of the portfolio date. This value is significant in that it is the last known price at which the security was still held.
An asterisk sign (*) next to the price indicates that the price is likely invalid.